Effects of Semaglutide Combined with Intensive Insulin Pump Therapy on Endocrine Metabolism in Patients with Type 2 Diabetes Mellitus
LI Yuan-hong, MA Lin-na
2022, 40(23):
11-14.
Asbtract
(
398 )
PDF (2016KB)
(
45
)
References |
Related Articles |
Metrics
Objective To investigate and analysis the effect of semaglutide combined with intensive insulin pump therapy on endocrine metabolism in patients with type 2 diabetes mellitus (T2DM). Methods A total of 60 patients with type 2 diabetes mellitus who were treated in the Endocrinology Department of the Fourth Hospital of Harbin were selected as the research subjects from September 2021 to March 2022, according to the random number table method, the patients were divided into the semaglutide group and the control group, with 30 cases in each group. The control group was given intensive insulin pump therapy, and the semaglutide group was given semaglutide treatment on the basis of the treatment of the control group. Both groups were treated for 3 months, and the endocrine and metabolic changes of the patients were measured and recorded. Results After treatment, the fasting blood glucose and 2 h postprandial blood glucose of the semaglutide group and the control group were significantly lower than those before treatment (P<0.05), and the semaglutide group was also significantly lower than the control group (P<0.05). After treatment, the levels of total cholesterol, low-density lipoprotein cholesterol and triglyceride in the two groups were significantly lower than those before treatment (P<0.05), and high-density lipoprotein cholesterol was higher than that before treatment (P<0.05), the levels of total cholesterol, low-density lipoprotein cholesterol and triglyceride in the semaglutide group were significantly lower than those in the control group (P<0.05), and high-density lipoprotein cholesterol was higher than the control group (P<0.05). After treatment, the glycosylated hemoglobin in the two groups was significantly lower than that before treatment (P<0.05), and the C-peptide was significantly higher than that before treatment (P<0.05), the glycosylated hemoglobin in the semaglutide group was significantly lower than that in the control group (P<0.05), and the C-peptide was significantly higher than that in the control group (P<0.05). The quality of life scores of vitality, mental health, physiological function, social function, emotional function, physiological function, general health, and physical pain in the semaglutide group after treatment were significantly higher than those in the control group (P<0.05). Conclusion The application of semaglutide combined with intensive insulin pump therapy in patients with type 2 diabetes mellitus can promote the reduction of fasting blood glucose, 2 h postprandial blood glucose, and glycosylated hemoglobin levels, increase the level of C-peptide in patients, and also improve the level of blood lipids in patients and quality of life of patients.